Novel Strategy to Prevent Otitis Media Caused by Colonizing Streptococcus pneumoniae
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In early childhood, 70%–83% of children experience at least one episode of acute otitis media (AOM) [1,2]. Streptococcus pneumoniae is the most common bacterial agent identified as the causative agent of these infections, although there is increasing evidence that a variety of respiratory viruses play a prominent role in the development and pathogenesis of AOM [1]. Even though the heptavalent pneumococcal conjugate vaccine appears to be making an impact on the incidence of this disease among children in the United States, AOM (with more than 24 million diagnoses annually) remains the leading reason for physician visits and antibiotic prescriptions among preschool-aged children [2,3]. Frequent use of antibiotics for AOM has led to a vicious cycle of diminishing returns: increased exposure has led to increasing drug resistance, which in turn makes the infections more difficult to treat, necessitating new drugs and more treatment. Recently, purified bacteriophage (phage) cell wall hydrolases, or lysins, have shown promise as novel anti-infectives due to their ability to eradicate nasal carriage of gram-positive pathogens, particularly S. pneumoniae [4,5]. These highly active enzymes are produced by phages to disrupt the bacterial cell wall for the release of progeny phage. Here, we show that the Cpl-1 lysin, which is specific for S. pneumoniae [6], prevents AOM in a novel mouse model that mimics the natural pathogenesis of this common infection. Current animal models for AOM have critical limitations. Modeling AOM in mice requires invasive and artificial procedures to establish infection, and sacrifice of the animals to determine outcomes. Larger animals such as chinchillas and ferrets may develop infection by more natural routes, but use of these models is limited by their size and complexity [7,8]. Ideally, we wished to develop a non-invasive mouse model that was permissive of natural infection. We engineered a piliated strain of S. pneumoniae, known to efficiently colonize mucosal surfaces (a type 19F strain obtained from B. Henriques-Normark, ST16219F) [9], to express luciferase [10]. Groups of five mice maintained in a BL2 facility were infected intranasally with 1 × 105 or 1 × 106 colony-forming units (CFU) of this bioluminescent strain under light anesthesia with 2.5% inhaled isoflurane using an established infection model approved by the St. Jude Children's Research Hospital animal care and use committee [11]. Animals were followed daily for development of infection for two weeks and thrice weekly for another four weeks. Within 72 hours of pneumococcal infection, 100% of mice (10/10) were visibly colonized with bacteria in the anterior portion of their nose, and 70% (7/10) had developed AOM. These infections of the middle ear all resolved by bioluminescent imaging within 48 hours, and no mice had evidence of AOM six days after challenge or later. Nasal colonization persisted for a median of 27 days (range 17–34 days). Around half of all children are colonized with S. pneumoniae [12]. Alteration of eustachian tube function or disruption of mucosal surfaces through viral infection allows colonizing bacteria to ascend into the middle ear, triggering AOM [1]. To model this phenomenon, we infected mice that had been stably colonized by pneumococcus with influenza virus and followed them for development of AOM. Although all mice had been colonized prior to infection with virus, 63% of virus-infected mice (19/30) developed AOM compared to 0% (0/10) of mice mock-infected with phosphate buffered saline (PBS) (Figure 1). Twenty-one of thirty mice in the virus group had experienced AOM after introduction of the bacteria in the first 72 hours post colonization (with resolution before viral challenge), while eight of ten mice in the PBS control group had experienced AOM with resolution (unpublished data). Both de novo and recurrent infections were seen in the virus-infected mice, with no correlation to whether they had previously had AOM. This is the first mouse model of AOM in which infection develops in a manner analogous to that observed in children. Figure 1 Visualization of Bioluminescent Bacteria Inside Live, Anesthetized Animals Shows the Induction of Otitis Media Using this novel and powerful model, we sought to test our hypothesis that reduction or elimination of colonizing pneumococci with purified Cpl-1 lysin [6] would prevent the development of AOM. Prior to infection with influenza virus, mice colonized with pneumococcus for seven days were treated twice four hours apart with either 1,000 ug of Cpl-1 intranasally or enzyme buffer (mock treatment). At the time of the second treatment, nine of ten animals (90%) had cleared the pneumococcus from the nose, compared to zero of ten (0%) treated with enzyme buffer. The Cpl-1 lysin was 100% effective in preventing AOM, as no animal treated with lysin developed a secondary bacterial infection following influenza infection, while eight of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insights into the Interaction between Influenza Virus and Pneumococcus
McCullers, J. A. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-05 · Cited by 846 · cited 1×
“Secondary bacterial infections account for much of the morbidity and approximately 25% of all deaths during seasonal epidemics of influenza, as well as 50%–95% of deaths during pandemics of influenza [14].”
Self-citationA role for Streptococcus pneumoniae in virus-associated pneumonia
Madhi, S. A., Klugman, K. P., & The Vaccine Trialist Group (2004) · Nature Medicine · doi:10.1038/nm1077 · Cited by 565 · cited 1×
“may prevent many cases of AOM, particularly those with chronic AOM. Importantly, these data also suggest that elimination or even reduction of resident pathogenic bacteria can prevent secondary bacterial complications of influenza. In support of this view, a recent study of a pediatric pneumococcal vaccine in South Af…”
Bacterial sinusitis and otitis media following influenza virus infection in ferrets
Peltola, V. T., Boyd, K. L., McAuley, J. L., Rehg, J. E., & McCullers, J. A. (2006) · Infection and Immunity · doi:10.1128/iai.74.5.2562-2567.2006 · Cited by 95 · cited 1×
“Larger animals such as chinchillas and ferrets may develop infection by more natural routes, but use of these models is limited by their size and complexity [7,8].”
Self-citation
Cited by
Bacteriophage Endolysins as Novel Antimicrobials
Schmelcher, M., Donovan, D. M., & Loessner, M. J. (2012) · Future Microbiology · doi:10.2217/fmb.12.97 · Cited by 785
Bacteriophage lysins as effective antibacterials
Fischetti, V. A. (2008) · Current Opinion in Microbiology · doi:10.1016/j.mib.2008.09.012 · Cited by 477
“Treatment of these mice with Cpl-1 lysin before influenza challenge was 100% effective at preventing the development of otitis media [55].”
Self-citationBacteriophage endolysins: A novel anti-infective to control Gram-positive pathogens
Fischetti, V. A. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.04.002 · Cited by 438
Self-citationNelson, D. C., Schmelcher, M., Rodriguez-Rubio, L., Klumpp, J., Pritchard, D. G., Dong, S., & Donovan, D. M. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00007-4 · Cited by 372
Bacteriophage and their lysins for elimination of infectious bacteria
O'Flaherty, S., Ross, R. P., & Coffey, A. (2009) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2009.00176.x · Cited by 272
Metadata
- Authors
- McCullers, J. A., Karlström, Å., Iverson, A. R., Loeffler, J. M., & Fischetti, V. A.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-03-23
- Volume
- 3
- Issue
- 3
- Pages
- e28
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2077728846
- Cited by
- 110
- References
- 3
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Strategy to Prevent Otitis Media Caused by Colonizing Streptococcus pneumoniae. https://app.cochat.ai/papers/10.1371/journal.ppat.0030028
- The paper
- McCullers, J. A., Karlström, Å., Iverson, A. R., Loeffler, J. M., & Fischetti, V. A. (2007). Novel Strategy to Prevent Otitis Media Caused by Colonizing Streptococcus pneumoniae. PLoS Pathogens. https://doi.org/10.1371/journal.ppat.0030028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.